Selection of blockbuster announcements

1、$Ping An Insurance (02318.HK) $From January to November, the original premium income reached 691.62 billion yuan.

Ping An Insurance announced that from January to November 2021, the company's holding subsidiaries Ping an property Insurance, Ping an Life Insurance, Ping an Endowment Insurance and Ping an Health Insurance realized the premium income of the original insurance contract of 243.32 billion yuan, 416.68 billion yuan, 20.834 billion yuan and 10.786 billion yuan respectively, totaling about 691.62 billion yuan.

2、$XIAOMI Group-W (01810.HK) $On December 14, 2.65 million shares were repurchased at a cost of HK $49.1708 million

XIAOMI Group announced on the Hong Kong Stock Exchange that it repurchased 2.65 million shares at a price between HK $18.40 and HK $18.64 on December 14, at a cost of HK $49.17075 million.

3、$Broad Pharmaceutical (00512.HK) $STC3141 carried out the IIa phase pilot trial in Europe for the treatment of COVID-19. All patients were given drugs in the group.

Broad Pharmaceutical announced that STC3141, a global innovative drug being developed by the group's subsidiary Grand Medical Pty Ltd (an innovative drug research and development center set up by the group in Australia), was successfully completed in Europe for the treatment of critical COVID-19 IIa phase clinical trials a few days ago, and successfully completed 72 hours of continuous intravenous administration of the tested patients for 30 days after treatment. The clinical study report is expected to be completed within the next 6 months.

4、China Metallurgical Industry (01618.HK) $The value of newly signed contracts from January to November was 1.07067 trillion yuan, an increase of 19.7% over the same period last year.

China MCC announced that it signed new contracts worth 1.07067 trillion yuan from January to November 2021, an increase of 19.7% over the same period last year.

5、Poly Xiexin Energy (03800.HK) $A maximum of 2.037 billion shares are proposed to be placed, with a net fund of about HK $4.994 billion

Poly Xiexin Energy announced that on December 15, 2021, the company entered into a placing agreement with the exclusive placing agent to place up to 2.037 billion shares at a placing price of HK $2.49 per share, a discount of about 2.4 per cent to the closing price of HK $2.55 on December 14, 2021.

The placing shares are equivalent to about 8.13% of the total issued share capital of the company at the date of the announcement and about 7.52% of the total issued share capital of the company after the expansion of the allotment and issuance of placing shares. Assuming that all the placing shares are informed of the placing, the total amount of proceeds from the expected placing will be about HK $5.071 billion, while the total net proceeds from the expected placing will be approximately HK $4.994 billion. The company intends to use the net proceeds from the placing for capital expenditure and general working capital purposes.

• Listing of new shares

Cornell Optics (02276): 1.78 times subscribed for the public offering at HK $4.46 per share

Celadon Game (06633): about 3.64 times subscribed for the public offering at HK $11.20 per share

• Important matters

Chinalco International (02068): abnormal volatility in A-share trading, relatively small proportion of lithium-related business income

Huabao International (00336): the stock price has fluctuated abnormally recently, so it is proposed to spin off the condiment business and list it on the Stock Exchange.

Yuexiu Transportation Infrastructure (01052): complete the divestment of highway assets, Huaxia Yuexiu Expressway REIT listed on Shenzhen Stock Exchange

Country Garden Services Holdings (06098): Yang Huiyan, the controlling shareholder, promised not to reduce the company's shares within half a year.

New City Hyatt Service (01755): affiliated with Shanghai Jiamu to enter into 2022 office lease agreement

Yixin Group (02858): enter into a business cooperation framework agreement with Dalian Rongxin

Kangzhe Pharmaceutical (00867): through affiliated cooperation with OVMEDI, a first-tier medical and beauty company in South Korea, to reach a cooperation on buried thread implantation products.

Xiansheng Pharmaceutical (02096): strategic Cooperation with Avilex to introduce innovative PSD- 95 dimer Inhibitors

De Yongjia Group (00321): cotton and cotton yarn stored in the warehouse in Dongguan, Guangdong were damaged by fire.

Fuhui International Group Holdings (01034): Fuhui Biotechnology settled in Sanya Yazhou Science and Technology City, and reached strategic cooperation with Hainan Travel Control Group and Hainan Sanchuang Culture.

CSPC Pharmaceutical (01093): the first patient administration was completed in the United States in the Phase 2 clinical trial of JMT601 1amp.

HUTCHMED (China) Limited (00013): HMPL-523 clinical data released at the annual meeting of the American Hematological Society in 2021

Green Leaf Pharmaceutical (02186): BA1201, an innovative antibody drug for the treatment of advanced solid tumor, has been approved for clinical trial in China.

Yasheng Medicine-B (06855): the latest research progress of three new drugs and six studies were announced at the 63rd Annual meeting of the American Hematological Society.

BeiGene, Ltd. (06160): reached a global license and cooperation agreement with Weibo for anti-LAG-3 antibody LBL-007, which will be granted an exclusive commercial license outside China.

Shisiyao Group (02005): "Hydroxyethyl starch 130 swab 0.4 Sodium Chloride injection" approved by the State Drug Administration and passed the consistency evaluation of the quality and efficacy of generic drugs.

Broad Pharmaceutical (00512): the phase IIa clinical trial of global innovative product STC3141 in Europe for the treatment of COVID-19 has been completed for all patients to be administered in the group.

• Financial report data

China Mobile Limited (00941): the net profit of returning home in the first three quarters increased by 6.6% over the same period last year to 86.962 billion yuan.

Ping An Insurance (02318): the premium income of 4 subsidiaries reached 691.62 billion yuan in the first 11 months.

China MCC (01618): newly signed contracts worth 1.07067 trillion yuan from January to November, an increase of 19.7% over the same period last year

Cathay Pacific (00293): about 70, 000 passengers in November, an increase of 85.2% over the same period last year

Zhongan Online (06060): the original insurance premium income from January to November was 18.701 billion yuan, an increase of 27.3% over the same period last year.

Sony Holdings Group (02103): realized contract sales of 80.93 billion yuan in the first November.

Maple Leaf Education (01317): annual loss attributable to shareholders 3.1276 billion yuan, resumption of trading on December 14

Yida China (03639): contract sales in the first 11 months reached 4.185 billion yuan

• Merger and acquisition and sale

Zhongli Group (00382): plans to acquire a secondary vocational training school in Guangdong with 150 million yuan

Greentown Service (02869): plan to buy 51% stake in Zhejiang Luke for 209 million yuan

Sun City Group (01383): plans to sell aircraft for $10 million

• Additional placement

China Mobile Limited (00941): plans to list no more than 845.7 million A-shares on the Shanghai Stock Exchange

Chunli Medical (01858): plans to issue 38.428 million A shares to be listed on the Kechuang Board of Shanghai Stock Exchange.

Shimao Group (00813): issue 145 million shares under general authorization at an issue price of HK $8.14 per share

Genscript Biotech Corporation (01548): Legend Biotech Corp plans to sell $300m of American depositary shares to the public

Poly Xiexin Energy (03800): plans to place up to 2.037 billion shares, net raising about HK $4.994 billion

• Repurchase cancellation

XIAOMI (01810): repurchased 2.65 million shares at a cost of HK $49.1708 million on December 14

Sunac Services (01516): repurchased 5 million shares at a cost of HK $43.2385 million on December 14

HSBC Holdings PLC (00005): spent 21.752 million pounds to buy back 5.008 million shares on December 13th

CK Hutchison (00001): repurchased 231500 shares at a cost of HK $11.5213 million on December 14

Ping An Healthcare And Technology (01833): repurchased 1.7736 million shares at a cost of HK $54.4064 million on December 14

Hopson Development (00754): repurchased 1.91 million shares at a cost of HK $29.9 million on December 14

Shimao Service (00873): repurchased 2 million shares at a cost of HK $10.6414 million on December 14